Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Orient Pharma Co's annualized net income for the quarter that ended in Dec. 2025 was NT$367 Mil. Orient Pharma Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$2,098 Mil. Therefore, Orient Pharma Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 17.51%.
The historical rank and industry rank for Orient Pharma Co's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:4166'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -22.33 Med: -10.99 Max: 12.54
Current: 12.54
During the past 13 years, Orient Pharma Co's highest Return-on-Tangible-Equity was 12.54%. The lowest was -22.33%. And the median was -10.99%.
ROCO:4166's Return-on-Tangible-Equity is ranked better than 64.48% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs ROCO:4166: 12.54
Orient Pharma Co (ROCO:4166) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Orient Pharma Co Return-on-Tangible-Equity Related Terms
Orient Pharma Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Orient Pharma Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4166 vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Pharma Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Orient Pharma Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 17.51% mean?
Orient Pharma Co (ROCO:4166) has a Return-on-Tangible-Equity of 17.51% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Orient Pharma Co and its competitors. According to the industry distribution chart, Orient Pharma Co ranks #320 out of 901 companies in the Drug Manufacturers industry, placing it in the top 35.5%.
Is Orient Pharma Co's Return-on-Tangible-Equity too high?
Orient Pharma Co's current Return-on-Tangible-Equity is 17.51%. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Orient Pharma Co's value of 17.51% is 121.6% above this industry median. Based on the distribution chart, Orient Pharma Co ranks #320 out of 901 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orient Pharma Co has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #320 out of 901 companies for Return-on-Tangible-Equity. This puts Orient Pharma Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Orient Pharma Co's value of 17.51% is 121.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Pharma Co's current Return-on-Tangible-Equity of 17.51% is 121.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Orient Pharma Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current Return-on-Tangible-Equity is 17.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.26, compared to a current price of NT$26.15 — trading 42.2% below its estimated fair value. The current Return-on-Tangible-Equity is 17.51% and 121.6% above the Drug Manufacturers industry median of 7.90. Orient Pharma Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Return-on-Tangible-Equity is 17.51% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued.
The current stock price of NT$26.15 is trading 42.2% below its estimated GF Value™ of NT$45.26.
GuruFocus considers Orient Pharma Co to be Significantly Undervalued.
Key valuation signals for ROCO:4166:
Return-on-Tangible-Equity: 17.51%
GF Value™: NT$45.26 vs. price of NT$26.15 (42.2% below fair value)
Industry Position: 121.6% above the Drug Manufacturers median (#320 of 901)
No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
61GF Score
Get the complete analysis for ROCO:4166
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4166 has been successfully added to your 
